Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo
about
Tumor necrosis factor receptor 2: its contribution to acute cellular rejection and clear cell renal carcinomaModeling the intra- and extracellular cytokine signaling pathway under heat stroke in the liverInduction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infectionDecoy Strategies: The Structure of TL1A:DcR3 ComplexEarly immune responses accompanying human asymptomatic Ebola infectionsEffect of PGE1 on TNF-alpha status and hepatic D-galactosamine-induced apoptosis in ratsThe locus of tumor necrosis factor-alpha action in lung inflammationThe effector T cell response to influenza infectionEffect of soluble P55 tumour-necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions.Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.Protective effect of melatonin against liver injury in mice induced by Bacillus Calmette-Guerin plus lipopolysaccharide.Circulating tumor necrosis factor alpha (TNF), soluble TNF receptors, and interleukin-6 in human subacute bacterial endocarditis.Reduction of circulating cholesterol and apolipoprotein levels during sepsis.Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia.Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.Increased leptin expression in mice with bacterial peritonitis is partially regulated by tumor necrosis factor alpha.Levels of inhibitors of tumor necrosis factor alpha and interleukin 1beta in urine and sera of patients with urosepsis.The evolution of an inflammatory response.Etanercept: therapeutic use in patients with rheumatoid arthritisPEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.Clinical implications of tumour necrosis factor alpha antagonism in patients with congestive heart failure.Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and womenMaternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia.Tumor necrosis factor-alpha regulates secretion of the adipocyte-derived cytokine, leptin.Soluble tumor necrosis factor alpha receptors in sera from leprosy patients.Chronic hepatosplenomegaly in African school children: a common but neglected morbidity associated with schistosomiasis and malaria.Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.Apoptosis in diseases of the liver.The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation.A predominantly anti-inflammatory cytokine profile is associated with disease severity in meningococcal sepsisInflammation imaging of atherosclerosis in Apo-E-deficient mice using a (99m)Tc-labeled dual-domain cytokine ligand.Effect of laparoscopy on immune function.A glossary of circulating cytokines in chronic heart failure.Increased concentrations of tumour necrosis factor (TNF) and soluble TNF receptors in biliary obstruction in mice; soluble TNF receptors as prognostic factors for mortality.Falling into TRAPS--receptor misfolding in the TNF receptor 1-associated periodic fever syndromeTumor necrosis factor-α signaling in macrophages.Activation of TNFR1 ectodomain shedding by mitochondrial Ca2+ determines the severity of inflammation in mouse lung microvessels.The role of tumor necrosis factor alpha blockade in the treatment of congestive heart failure.Enhancement by galactosamine of lipopolysaccharide(LPS)-induced tumour necrosis factor production and lethality: its suppression by LPS pretreatment.Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels.
P2860
Q27007477-102283F5-6B36-45A3-BBE6-BC5A25B9DDEDQ27307863-10B4DC99-61F7-4FB7-ADD6-E37F65B4A099Q27480421-251DE088-34C5-44C5-B8CF-892ABDC7BD20Q27666869-97A0FE1F-02F1-4CED-8B73-E5FD90DC8CB7Q28344889-B911F3C0-CF5E-4B30-9D1A-FE571A7193EEQ28374442-4D870DDC-24B6-4439-BB03-55B57871996CQ28507632-BA5C67F5-A44E-430D-AC65-EF4B58B7F6E9Q30361773-7290C4EF-423F-4ACB-9C5B-19497800EC81Q30443950-3B4FF275-AA90-4202-B1E4-1D569AA03C40Q33178477-397BE3C1-3A37-451A-829A-A0A362FA4CFEQ33205953-0DAF2143-3EB8-4BC7-9D23-98E0C0F1FB8EQ33618298-8AF59C91-583F-4CEB-97A2-A0296332DADEQ33649891-6CF9ACC4-DBE0-4215-A09A-8ED87695072EQ33650241-E080F285-166F-4DF8-9F4F-3130F2EEA27BQ33741548-20106A2A-58D9-4A0D-9AD7-B75449145C67Q33752911-A86258F9-5752-42F3-8898-1EC06D813B86Q33757212-5B1AB326-071F-44C0-A62C-CC1CD39877CDQ33762821-AFE0852D-6F56-47CC-BE8D-A65114B0B2D8Q33782355-FBE20384-8C4B-430C-970E-F8FB82277632Q33782360-8499B534-9EE3-463F-B735-86E3BAD16807Q33782381-BF9BEA89-2C8B-42A1-87AF-73B4749AC873Q33800888-21B17135-8664-4F13-8E15-09C975A7FB83Q33821579-E5ABA0A6-DC89-41C5-9773-A838517DBE86Q33966320-54C4E2DA-8709-42CD-8D3E-388AA03C69ABQ34000080-C0CBE561-EDBB-406C-8F23-7092E4948A80Q34017976-14E844D7-C665-4B65-AE73-7A4BF2FBE481Q34146304-A02A7917-1526-449B-89D6-350E6CECC5CEQ34248399-877DB822-2A9D-4C7B-9C79-07FFB4FEA0C7Q34249837-1C579EDE-0EEF-47C4-BCBF-73682102D5C0Q34293604-1B4FEFBA-4FAC-4FA2-A852-054930457B4CQ34315928-2A2CC00E-D730-41DF-BB86-EED7F9A988E1Q34385769-18161EF1-2535-48D7-8710-7BB76B66556EQ34398220-C91CDFF5-AB0D-4EDF-A835-39A5AE162265Q34409484-FD9069A2-5E73-4B92-ADC5-5CA0957C66E5Q34657952-29F6BAAE-89BB-491B-B1B6-A66D26D41DB0Q34734335-7B2F80D2-C9BB-4E8C-B191-03AFF1632FA2Q34876449-000771AD-E747-457A-AF7A-F3CB8969076CQ34943476-B53513FA-1D85-4BCA-A1E3-8A0893B74E4BQ35041408-4F3E90CC-D2CE-4BA1-AB27-3B83920F8F29Q35074866-D0CED7F5-B203-45CA-9A38-B72537717AAA
P2860
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1992
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor necrosis factor soluble ...... tor alpha in vitro and in vivo
@en
Tumor necrosis factor soluble ...... or alpha in vitro and in vivo.
@nl
type
label
Tumor necrosis factor soluble ...... tor alpha in vitro and in vivo
@en
Tumor necrosis factor soluble ...... or alpha in vitro and in vivo.
@nl
prefLabel
Tumor necrosis factor soluble ...... tor alpha in vitro and in vivo
@en
Tumor necrosis factor soluble ...... or alpha in vitro and in vivo.
@nl
P2093
P2860
P356
P1476
Tumor necrosis factor soluble ...... tor alpha in vitro and in vivo
@en
P2093
P2860
P304
P356
10.1073/PNAS.89.11.4845
P407
P577
1992-06-01T00:00:00Z